Rony Dahan, PhD

Principal Investigator at Weizmann Institute of Science

Speaker

Dr. Rony Dahan is an assistant professor in the Department of Systems Immunology at the Weizmann Institute of Science. His research focuses on cancer immunity and immunotherapy, specifically enhancing immune responses against cancer through innovative antibody engineering and detailed studies of FcγR pathways. During his postdoctoral work (2013-2017) at Rockefeller University with Prof. Jeffrey Ravetch, Dr. Dahan made critical contributions to the development of the Fc-engineered CD40 antibody, 2141-V11, now in Phase II clinical trials. Since founding his lab in 2017, he has pioneered novel immunotherapies, including bispecific antibodies and dendritic-T cell engagers, with several therapies advancing through clinical development. His work continues to shed new light on the mechanisms of action of immunotherapies, addressing key challenges in the field.